JP2022531814A5 - - Google Patents

Info

Publication number
JP2022531814A5
JP2022531814A5 JP2021540137A JP2021540137A JP2022531814A5 JP 2022531814 A5 JP2022531814 A5 JP 2022531814A5 JP 2021540137 A JP2021540137 A JP 2021540137A JP 2021540137 A JP2021540137 A JP 2021540137A JP 2022531814 A5 JP2022531814 A5 JP 2022531814A5
Authority
JP
Japan
Prior art keywords
antigen
cell
composition
domain
binding molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021540137A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022531814A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/013099 external-priority patent/WO2020146743A1/en
Publication of JP2022531814A publication Critical patent/JP2022531814A/ja
Publication of JP2022531814A5 publication Critical patent/JP2022531814A5/ja
Pending legal-status Critical Current

Links

JP2021540137A 2019-03-12 2020-01-10 改変細胞の増幅およびその応用 Pending JP2022531814A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962817322P 2019-03-12 2019-03-12
PCT/US2020/013099 WO2020146743A1 (en) 2019-01-10 2020-01-10 Modified cell expansion and uses thereof

Publications (2)

Publication Number Publication Date
JP2022531814A JP2022531814A (ja) 2022-07-12
JP2022531814A5 true JP2022531814A5 (https=) 2023-01-20

Family

ID=82361690

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021540137A Pending JP2022531814A (ja) 2019-03-12 2020-01-10 改変細胞の増幅およびその応用

Country Status (1)

Country Link
JP (1) JP2022531814A (https=)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016138846A1 (en) * 2015-03-02 2016-09-09 Shanghai Sidansai Biotechnology Co., Ltd Reducing immune tolerance induced by pd‐l1
JP6961490B2 (ja) * 2015-04-08 2021-11-05 ノバルティス アーゲー Cd20療法、cd22療法、およびcd19キメラ抗原受容体(car)発現細胞との併用療法
EP3347026A4 (en) * 2015-09-09 2019-05-08 Seattle Children's Hospital (DBA Seattle Children's Research Institute) GENEMANIPULATION OF MACROPHAGES FOR IMMUNOTHERAPY
KR20180118175A (ko) * 2016-03-04 2018-10-30 노파르티스 아게 다중 키메라 항원 수용체 (car) 분자를 발현하는 세포 및 그에 따른 용도
US20220265708A1 (en) * 2018-01-11 2022-08-25 Innovative Cellular Therapeutics, Inc. Modified Cell Expansion and Uses Thereof
US20210379149A1 (en) * 2018-10-25 2021-12-09 Innovative Cellular Therapeutics Holdings, Ltd. Increasing or Maintaining T-Cell Subpopulations in Adoptive T-Cell Therapy
US20220000921A1 (en) * 2018-11-20 2022-01-06 Innovative Cellular Therapeutics Holdings, Ltd. Modified Cell Expressing Therapeutic Agent and Uses thereof

Similar Documents

Publication Publication Date Title
US20200038443A1 (en) Multi-function and multi-targeting car system and methods for use thereof
JP2022550899A5 (https=)
JP2022541441A5 (https=)
JP7767502B2 (ja) Nk阻害性分子を発現する遺伝子改変免疫細胞とその使用
EP4274586A1 (en) Car cells and polyspecific binding molecules for treating solid tumor
JP2020517295A5 (https=)
JP2021536265A5 (https=)
JP2021527689A5 (https=)
EP4148125A1 (en) Engineered immune cell for allotransplantation
JP2024023228A5 (https=)
JP2023505206A5 (https=)
JP2024534471A5 (https=)
JP2023548467A5 (https=)
JP2023548829A5 (https=)
EP3909590A1 (en) Cellular immunotherapy combination
JP2023549098A5 (https=)
JP2024534417A5 (https=)
EP4194472A1 (en) Chimeric antigen receptor comprising novel co-stimulatory domain and use thereof
JP2023521519A5 (https=)
JP2024515189A5 (https=)
JP2022513372A5 (https=)
JP2024509917A5 (https=)
IL313588A (en) Use of dual cytokine fusion proteins comprising il-10 and adoptive cell therapies or bispecific t-cell engagers to treat cancer
JP2024536859A5 (https=)
JP2023545992A5 (https=)